Quoin Pharmaceuticals (NASDAQ:QNRX) Releases Quarterly Earnings Results, Misses Expectations By $6.39 EPS

Quoin Pharmaceuticals (NASDAQ:QNRX) issued its quarterly earnings data on Tuesday. The company reported ($6.50) EPS for the quarter, missing the consensus estimate of ($0.11) by ($6.39), Zacks reports.

Quoin Pharmaceuticals Price Performance

Shares of QNRX opened at $6.36 on Wednesday. Quoin Pharmaceuticals has a one year low of $5.01 and a one year high of $54.95. The firm has a market capitalization of $3.74 million, a P/E ratio of -1.57 and a beta of 1.39. The business has a fifty day moving average of $7.87 and a 200 day moving average of $15.17.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.